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ttp://dx.doi.org/10.1016/j.ajpath.2012.11.008Caveolin-1 (Cav1) is a scaffolding protein that serves to regulate the activity of several signaling
molecules. Its loss has been implicated in the pathogenesis of several types of cancer, but its role in the
development and progression of cutaneous squamous cell carcinoma (cSCC) remains largely unexplored.
Herein, we use the keratinocyte cell line PAM212, a murine model of cSCC, to determine the function of
Cav1 in skin tumor biology. We ﬁrst show that Cav1 overexpression decreases cell and tumor growth,
whereas Cav1 knockdown increases these attributes in PAM212 cells. In addition, Cav1 knockdown
increases the invasive ability and incidence of spontaneous lymph node metastasis. Finally, we
demonstrate that Cav1 knockdown increases extracellular signalingerelated kinase 1/2 mitogen-
activated protein kinase/activator protein-1 pathway activation. We attribute the growth and
invasive advantage conferred by Cav1 knockdown to increased expression of activator protein-1 tran-
scriptional targets, including cyclin D1 and keratin 18, which show inverse expression in PAM212 based
on the expression level of Cav1. In summary, we demonstrate that loss of Cav1 affects several char-
acteristics associated with aggressive human skin tumors and that this protein may be an important
modulator of tumor growth and invasion in cSCC. (Am J Pathol 2013, 182: 992e1004; http://
dx.doi.org/10.1016/j.ajpath.2012.11.008)Supported by an American Heart Association grant (Beginning Grant-in-
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squamous cell carcinomas, is the most prevalently diag-
nosed malignancy among white populations, and its inci-
dence is increasing worldwide.1e3 Unlike basal cell
carcinomas, cutaneous squamous cell carcinomas (cSCCs)
can be aggressive cancers that carry a signiﬁcant risk of
metastasis. Of the 700,000 cSCCs diagnosed yearly in the
United States,3 approximately 5% will metastasize to lymph
nodes and distant organs.4,5 Various markers are used to
assess the risk for metastatic progression in these lesions:
tumor size and depth, degree of differentiation, and
involvement of vascular or lymphatic vessels, among
others.6,7 Thus, given the prevalence of SCCs and their
potential for developing into life-threatening malignancies,
the identiﬁcation of novel mechanisms contributing to
tumor development and progression into invasive lesionsstigative Pathology.
.could provide better prognostic markers to predict disease
outcome and improve therapeutic treatments.
Caveolae are a specialized form of membrane lipid raft
characterized as ﬂask-shaped cavities in the cell membrane.8,9
One of their main biological functions is signal transduction,
accomplished through the proteins that preferentially localize
Cav1 Modulates cSCC Growth and Invasionto these organelles.10 The essential protein components of
these cellular structures are the caveolins, encoded by three
different genes (CAV1, CAV2, and CAV3) that vary in their
tissue speciﬁcity.9,11,12 Caveolin-1 (Cav1) contains a scaf-
folding domain that compartmentalizes a multitude of
signaling molecules within caveolae, modulating their
activity and preferentially binding them in their inactive
state.9 Cav1, therefore, functions as a negative regulator of
numerous signaling molecules, and its misregulation, dele-
tion, or mutation has been implicated in the pathological
characteristics of a variety of human diseases, including
cancer.
Despite the substantial amount of research on the function
of Cav1 in various cancer types, its role in the pathogenesis
of nonmelanoma skin cancer remains largely unexplored.
Previous research has shown that Cav1 ablation in murine
skin increases basal layer proliferation13 and benign papil-
loma incidence, multiplicity, and size after carcinogenic
treatment.14 In addition, in human skin, Cav1 is lost during
the progression of psoriasis15,16 and signiﬁcantly decreased
in cutaneous squamous cell carcinoma.17 To further
examine the role of Cav1 in squamous cell carcinoma
development, we used a murine keratinocyte cell line,
PAM212, that is able to form squamous cell carcinomas
in vivo.18 By using this system, we were able to investigate
how altered Cav1 expression affects aspects of cancer
development and progression.
In the current study, we show that overexpression of Cav1
in PAM212 cells results in decreased cell proliferation
in vitro, which corresponds to a dramatic decrease in tumor
incidence and size in vivo. In contrast, the knockdown of
Cav1 in these cells increases tumor growth and enhances
their invasive ability both in vitro and in vivo. Mechanisti-
cally, Cav1 knockdown is associated with hyperactivation of
the extracellular signalingerelated kinase (Erk) 1/2 mitogen-
activated protein kinase (MAPK) signaling pathway and
increased activator protein (AP)-1 transcription factor acti-
vation in response to two different growth stimuli. We
implicate several AP-1eresponsive genes as mediators of the
proproliferative and invasive phenotype in Cav1 knockdown
PAM212 cells, as determined by quantitative RT-PCR (RT-
qPCR). Finally, we show that Cav1 overexpression in the
human cSCC cell line SCC13 decreases in vitro proliferation,
migration, and invasion, indicating that our results are able to
translate to human skin cancer. In summary, these results
demonstrate that loss of Cav1 negatively affects several
markers for metastatic potential in human skin tumors,
including tumor size and invasiveness, and this is mecha-
nistically associated with MAPK/AP-1 hyperactivation.
Materials and Methods
Materials
Antibodies and their sources were as follows: Cav1 (N-20),
cyclin D1, cyclin A, and matrix metalloproteinase 2 wereThe American Journal of Pathology - ajp.amjpathol.orgfrom Santa Cruz Biotechnology (Santa Cruz, CA). Cav2
and epidermal growth factor receptor (EGFR) were from
BD Biosciences (Franklin Lakes, NJ). Keratin 14 (K14) and
keratin 10 (K10) were from Covance (Princeton, NJ).
Keratin 18 (K18) and CD31 were from Abcam (Cambridge,
MA). Keratin 8 (K8) was from Epitomics (Burlingame,
CA). p-Histone H3 (S10) was from Upstate (Billerica, MA).
p-Erk (T202/Y204), Erk, p-EGFR (Y1173), c-Fos, p-c-Jun
(S73), c-Jun, and p-c-Jun N-terminal kinase (JNK; T183/
Y185) were from Cell Signaling Technology (Beverly,
MA). Glyceraldehyde-3-phosphate dehydrogenase was
from Fitzgerald (Acton, MA), and b-actin and b-tubulin
were from Sigma-Aldrich (St. Louis, MO). U0126 and
SP600125 were from Cell Signaling Technology and LC
Laboratories (Woburn, MA), respectively.
Cell Culture
PAM212 cells were a generous gift from Dr. Ulrich Rodeck
(Thomas Jefferson University, Philadelphia, PA). They were
maintained in RPMI 1640 medium supplemented with 10%
fetal bovine serum (FBS). HaCaT human immortalized
keratinocytes were maintained in Dulbecco’s modiﬁed
Eagle’s medium supplemented with 10% FBS. SCC13 cells
were obtained from The Harvard Skin Disease Research
Center (Boston, MA).19,20 They were maintained in a 1:1 mix
of Keratinocyte Serum Free Medium (Life Technologies,
Grand Island, NY) and DF-K medium (a 1:1 mix of calcium-
free Dulbecco’s modiﬁed Eagle’s medium and Ham’s F-12
Nutrient Mixture; Life Technologies) supplemented with 25
mg/mL bovine pituitary extract, 0.2 ng/mL EGF, and 0.3
mmol/L calcium chloride. All cells were kept in an incubator
at 37C with 5% CO2.
Stable Cell Lines
PAM212 and SCC13 cells were stably transduced to express
either pBabe or pBabe-Cav1.21 To stably knock down Cav1,
shRNA scramble control and predesigned shRNAs targeting
nucleotides 185 to 205 and 482 to 502 of Cav1 mRNA
(NM_007616.4)wereobtained fromInvitrogen (Carlsbad,CA)
and subcloned into the pQCXIP-GFP retroviral vector (Clon-
tech, Mountain View, CA). PAM212 cells were infected, and
a stable cell populationwas selected, as previously described.22
Successful overexpression and knockdown of Cav1 were
veriﬁed by usingWestern blot analysis. ForCav1 re-expression
in Cav1 knockdown cells, short hairpin RNAs (shRNAs)
speciﬁc for Cav1 (sh-Cav1) PAM212 cells were stably trans-
duced to express pBabe-Cav1 as above.TheCav1 expressed by
this vector is resistant to the sh-Cav1 constructs already being
expressed in these cells because of nucleotide mismatch.
Western Blot Analyses
Cells were lysed in a modiﬁed radioimmunoprecipitation
assay buffer and analyzed as previously described.23 Brieﬂy,993
Trimmer et alprotein was separated via an SDS-PAGE gel and transferred
to a nitrocellulose membrane. Membranes were blocked in
5% bovine serum albumin (BSA; Sigma-Aldrich) in Tris-
buffered saline with 0.1% Tween. Primary antibody
diluted in blocking buffer was added for either 1 hour at
room temperature or overnight at 4C. Membranes were
washed three times in wash buffer, and horseradish perox-
idaseeconjugated secondary antibody was added for 1 hour
at room temperature. After washing, signal was developed
using Pierce Chemiluminescent Substrate (Thermo Fisher
Scientiﬁc, Rockford, IL).
Confocal Microscopy
Cells were double immunostained for Cav1 and Cav2, as
previously described.21 Pro-Long Gold Antifade reagent
(Molecular Probes, Eugene, OR) was used to mount the
coverslips, which were subsequently imaged by confocal
microscopy (LSM 510.META.Confocal; Carl Zeiss Inc.,
Jena, Germany).
Growth Curves and Proliferation Assay
Proliferation was measured using a 5-bromodeoxyuridine
(BrdU) incorporation enzyme-linked immunosorbent assay
(Roche Diagnostics, Indianapolis, IN). Cells were labeled
with BrdU in RPMI 1640 medium with 10% FBS for 4
hours. Growth curves of PAM212 and SCC13 cells were
generated by plating 10.5 cells/cm2 and counting cell
number daily for 4 days. Alternatively, growth curves
were generated by MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium]
assays (Promega, Madison, WI) and performed according to
the manufacturer’s instructions.
Tumor/Metastasis Studies
PAM212 cells (5  106) were intradermally injected into the
back skin of 5- to 6-week-old BALB/c nude mice, as previ-
ously described.24 Overexpression and knockdown cells
were pair injected with their respective controls. Tumor
volume was calculated weekly using the following equation:
(width2  length)/2. For spontaneous metastasis studies, one
cell type per mouse was injected as previously described.
Tumors were surgically excised after 5 weeks, and mice were
sacriﬁced 4 weeks after excision and examined for visible
(macroscopic) lymph node metastasis.25 Mice were main-
tained in an animal barrier facility with a 12-hour light/dark
cycle with ad libitum access to chow. All mouse work was
conducted in accordance with Institutional Animal Care and
Use Committee approval.
RT-qPCR Data
RT-qPCR was performed using ready-to-use primers (Real
Time Primers, LLC, Elkins Park, PA) and SYBR master994mix (Applied Biosystems by Life Technologies). Quantita-
tive expression data were acquired using the ABI-Prism
7900HT Sequence Detection System (Applied Biosystems),
and results were analyzed by the DDCT method.
26
IHC Analysis
Tumor sections were stained for K18 expression using
standard immunohistochemical (IHC) techniques.14 Brieﬂy,
parafﬁn-embedded sections were rehydrated and antigen
retrieval was performed using citrate buffer. Endogenous
peroxidase activity was blocked with 3% H2O2, and sections
were blocked in 10% goat serum and incubated with
primary antibody overnight. After washing, sections were
incubated with biotinylated secondary antibody for
30 minutes, washed again, and incubated with streptavidin
for 30 minutes. After signal development with 3,30-
diaminobenzidene, slides were counterstained with hema-
toxylin, dehydrated, and mounted.
Growth Factor Stimulation
PAM212 cells were plated in normal medium, serum
starved for 18 hours in serum-free medium (SFM) with
0.1% BSA, and treated with 50 ng/mL EGF (Peprotech,
Rocky Hill, NJ) in SFM with 0.1% BSA. After treatment,
cells were lysed and used in Western blot analysis, as
previously described.
Inhibitor Treatments
PAM212 cells were pre-incubated with dimethyl sulfoxide
or 40 mmol/L inhibitor in SFM for 2 hours, and then stim-
ulated with 10% FBS with dimethyl sulfoxide or inhibitor
for 1 hour. After treatment, cells were lysed and used in
Western blot analysis, as previously described.
Migration and Invasion Assays
For PAM212 transwell assays, 105 cells (migration) or
1.5  105 cells (invasion) were suspended in 0.5 mL SFM
with 0.1% BSA and added to 8-mm transwell chambers (BD
Biosciences) without (migration) or with (invasion) Matri-
gel. Cells were allowed to migrate for 6 hours or invade for
18 hours, after which cells that failed to migrate or invade
were removed with a cotton swab. Cells were ﬁxed and
stained with 0.5% crystal violet in methanol. For assays
using EGF, 50 ng/mL EGF in SFM with 0.1% BSA was
used as the chemoattractant in the bottom well, and cells
were allowed to migrate for 24 hours or invade for 48 hours.
For inhibitor assays, dimethyl sulfoxide or inhibitor was
added to both the top chamber and the bottom well, and
cells were allowed to migrate for 24 hours or invade for 48
hours. For SCC13 assays, 7.5  104 cells (migration) or 105
cells (invasion) were plated using 10% FBS as the chemo-
attractant and allowed to migrate or invade for 24 hours.ajp.amjpathol.org - The American Journal of Pathology
Cav1 Modulates cSCC Growth and InvasionStatistical Analysis
All results are represented as means  SEM. Statistical
analyses were performed using Prism software version 4.0
(Graph Pad Software, Inc., San Diego, CA).
Results
Cav1 Overexpression Decreases in Vitro Proliferation
and in Vivo Tumor Incidence and Growth in PAM212
Keratinocytes
PAM212 murine keratinocytes were stably transduced to
express either pBabe empty vector or pBabe-Cav1 over-
expression vector. PAM212-Cav1 cells showed an approx-
imately twofold increase in Cav1 expression, whereas
Cav2, which colocalized with Cav1, remained unaffected.
In addition, the expression of K14, a marker of prolife-
rating keratinocytes, and K10, a marker of differentiating
keratinocytes, were unchanged by Cav1 overexpression
(Figure 1A). Furthermore, Cav1 overexpression diminished
the proliferative ability of PAM212 cells, as evidenced by
decreased BrdU incorporation and expression of cyclin D1
and p-histone H3 (Figure 1B).
To examine the in vivo impact of Cav1 overexpression,
pBabe andCav1 cells were intradermally pair injected into the
back skin of Nude mice. Beginning at 2 weeks after injection,
analysis of tumor growth revealed that Cav1 overexpression
signiﬁcantly decreased the tumorigenicity of PAM212 cells
(tumor incidence) from100% to 50% (Figure 1C). In addition,
overexpression of Cav1 reduced tumor volume by approxi-
mately 27-fold (Figure 1D) and tumorweight by 30-fold (data
not shown) by 5 weeks after injection. These data indicated2 wks 3 wks 4 wks 5 
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The American Journal of Pathology - ajp.amjpathol.orgthat Cav1 functions as a negative regulator of cell and tumor
growth in PAM212 cells.
Cav1 Knockdown Increases in Vitro Proliferation and
in Vivo Tumor Growth in PAM212 Keratinocytes
PAM212 cells that were stably transduced to express sh-
Cav1 displayed complete absence of Cav1 protein with
a concurrent decrease in Cav2 expression levels. Immuno-
blot analysis showed that K14 and K10 levels were unaf-
fected by Cav1 knockdown (Figure 2A). As previously
described in cells and the Cav1 knockout mouse, Cav1 and
Cav2 colocalize,27 and Cav1 is required to stabilize and
transport Cav2 to the plasma cell membrane.12 Accordingly,
confocal microscopy analysis revealed that Cav1 and Cav2
colocalized as normal in short hairpin control (shCtl) cells,
whereas in sh-Cav1 cells, Cav2 was mainly localized
around the nucleus (Figure 2B). These results indicated that
Cav1 knockdown in these cells closely mimicked the
phenotype observed in Cav1 knockout mice in that Cav2
was reduced and failed to localize to the membrane.
In addition, Cav1 knockdown signiﬁcantly enhanced the
proliferation of PAM212 cells in vitro, as demonstrated by
increasedBrdU incorporation and expressionof cyclinsD1 and
A (Figure 2C). To examine in vivo growth, Cav1 knockdown
and control cells were pair injected into the back skin of Nude
mice. Analysis of tumor volume revealed that Cav1 knock-
down PAM212 cells formed tumors that were signiﬁcantly
larger compared with shCtl cells throughout the entire study
(Figure 2D). By 5 weeks after injection, shCav1 tumors were
approximately ﬁvefold larger in volume and fourfold larger in
mass (Figure 2D). In addition, the effect of Cav1 knockdown
on in vitro proliferation and in vivo tumor growthwas validatedwks
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Figure 1 Cav1 overexpression decreases in vitro
proliferation and in vivo tumor incidence and growth
in PAM212 keratinocytes. A: Western blot analysis of
PAM212 cells retrovirally transduced with either
empty pBabe plasmid (pBabe) or pBabe-Cav1 over-
expression plasmid (Cav1) shows increased Cav1
expression, but no change in the expression of Cav2;
K14, a marker of proliferating keratinocytes; or K10,
a marker of differentiating keratinocytes. B: Cav1
PAM212 cells display reduced proliferation, as
determined by a BrdU incorporation assay (4 hours;
nZ16pergroup)anddecreased expressionof cyclin
D1 and p-histone H3 proteins. Cav1 overexpression
dramatically reduces tumor incidence (C) and growth
(D) in PAM212 cells intradermally injected in the
back skin of mice (nZ 10 per group). yP< 0.05 (by
Fisher’s exact test). Inset: Tumor growth 4 weeks
after injection. Results are reported asmeans SEM.
*P < 0.05, **P < 0.01 by the unpaired t-test.
GAPDH, glyceraldehyde-3-phosphate dehydroge-
nase.
995
Figure 2 Cav1 knockdown increases in vitro
proliferation and in vivo tumor growth in PAM212
cells. A: Western blot analysis of PAM212 cells
stably transduced via retroviral infection with
either scramble shCtl or shCav1. Cav1 knockdown
results in a decrease in Cav2 expression, whereas
K14 and K10 expression is unaffected. B: Confocal
microscopy of shCtl and shCav1 PAM212 cells
immunostained with antibodies against Cav1 and
Cav2. Hoechst 33342 is shown as a nuclear marker.
In the absence of Cav1, Cav2 remains sequestered
around the nucleus. C: Cav1 knockdown increases
the proliferative ability of PAM212 cells, as deter-
mined by a BrdU incorporation assay (4 hours;
n Z 4 per group) and increased expression of
cyclins A and D1. D: In vivo tumor growth was
assessed as in Figure 1D. Cav1 knockdown results in
a dramatic increase in tumor volume and weight.
Inset: Tumor growth 4 weeks after injection.
Results are reported as means  SEM. *P < 0.05,
**P < 0.01, and ***P < 0.001 by the unpaired t-
test. GAPDH, glyceraldehyde-3-phosphate dehy-
drogenase.
Trimmer et alusing a second shRNA construct (Supplemental Figure S1).
Cav1 ablation in these cells increased BrdU incorporation by
1.9-fold, tumor volume by 3.6-fold, and tumor weight by
2.3-fold. Finally, we showed that re-expressing an shRNA-
resistant Cav1 in both shCav1 cell lines rescued the increase
in cell growth caused by Cav1 knockdown in these cells
(Supplemental Figure S2). Collectively, these data illustrated
the growth-inhibitory function of Cav1 in PAM212 cells.Cav1 Knockdown Increases the Invasive and Metastatic
Ability of PAM212 Cells
To determine whether Cav1 knockdown affected the meta-
static ability of these cells, we undertook a spontaneous
metastasis study. Tumors were allowed to grow for 5 weeks
and were excised, and animals were examined for evidence of
visible lymph node metastasis 4 weeks after excision. Inter-
estingly, down-regulation of Cav1 signiﬁcantly increased the
incidence of visible lymph node metastasis from approxi-
mately 50% to approximately 100%. In addition, lymph
nodes dissected from animals with metastasis were signiﬁ-
cantly larger (approximately threefold) in mice injected with
shCav1 cells versus shCtl-injected animals (Figure 3A).996Todeterminewhy shCav1 tumors colonized a secondary site
with greater frequency, we examined the histological charac-
teristics of the primary tumors. Accordingly, histological
analysis revealed abundant keratin pearls (pink deposits) in
shCtl tumors, an indication of a well-differentiated lesion.28
shCav1 primary tumors also showed a dramatic increase in
the expression of K18, a marker for less-differentiated and
more invasive SCCs29e33 (Figure 3B). In addition, CD31
staining suggested that shCav1 tumors showed a trend toward
greater vessel density (Figure 3C), a requirement for tumor
growth and metastasis.34,35
Finally, we examined the in vitro migratory and invasive
ability of these cells using transwell assays. Cav1 knockdown
in PAM212 conferred an increased ability to migrate through
a transwell chamber by approximately fourfold and to invade
through Matrigel by 11-fold (Figure 3D). This enhanced
invasion was associated with increased expression of matrix
metalloproteinase 2, a protein involved in extracellular matrix
breakdown during tumor cell invasion and metastasis36,37;
K18; and its binding partner K8, which is also associated with
invasion29e33 (Figure 3E and Supplemental Figure S1). In
addition, overexpression of Cav1 had the opposite effect on
migration, invasion, and K8 and K18 expression (Figure 4, A
and B). Cav1 overexpression decreased K8 and K18ajp.amjpathol.org - The American Journal of Pathology
Figure 3 Cav1 knockdown increases the invasive
and metastatic ability of PAM212. A: Spontaneous
metastasis formation was examined 9 weeks after
intradermal injection of shCtl and shCav1 cells. Cav1
knockdown results in an increase in the incidence
of visible lymph node metastasis (approximately
twofold) and weight (n 15 per group). zP< 0.01 by
Fisher’s exact test. B: Representative H&E staining of
paired shCtl and shCav1 primary tumors demonstrate
that both cell types form squamous cell carcinomas.
There is increased expression of K18 in shCav1
tumors, indicative of a less-differentiated tumor. C:
CD31 IHC staining reveals a trend toward increased
vessel formation in Cav1 knockdown cells (n  4 per
group). D: By using 10% serum as a chemoattractant,
transwell migration and invasion assays show that
Cav1 knockdown dramatically increases the ability of
PAM212 to migrate through a transwell chamber and
invade through Matrigel (n Z 6 per group). E:
Western blot analysis of invasive markers shows that
Cav1 knockdown increases the expression of matrix
metalloproteinase (MMP) 2, K18, and its binding
partner, K8. Results are reported as means  SEM.
**P < 0.01, ***P < 0.001 by unpaired t-test. Scale
barZ 10 mm.
Cav1 Modulates cSCC Growth and Invasionexpression and migratory ability by threefold and invasive
ability by 1.9-fold. Collectively, these data suggested thatCav1
knockdown positively affected both the in vitro and in vivo
invasive capacity of these cells.
Cav1 Knockdown Increases MAPK Pathway Activation
in Response to Serum or Stimulation with EGF
To determine a mechanism by which Cav1 knockdown
enhanced tumor growth and invasion in PAM212 cells, we
examined signaling pathway activation in response to
various growth stimuli. When grown in medium containing
FBS, shCav1 PAM212 cells showed increased Erk1/2
activation, whereas p-EGFR expression levels were
unchanged. Serum-starved shCav1 PAM212 cells treatedThe American Journal of Pathology - ajp.amjpathol.orgwith EGF displayed enhanced p-EGFR at 1 minute after
treatment, and p-Erk1/2 expression levels increased after 1
and 10 minutes (Figure 5A). Notably, Cav1 knockdown
increased the ability of PAM212 cells to migrate through
a transwell chamber (approximately ninefold) and invade
through Matrigel (approximately twofold) when EGF was
used as a chemoattractant (Figure 5B).
An examination of signaling molecules downstream of
Erk1/2 activation revealed that shCav1 PAM212 cells
grown in medium containing FBS showed increased total
c-Fos and p-c-Jun levels. Similarly, serum-starved cells
treated with EGF showed increased total c-Fos and p-c-Jun
levels by 60 minutes after treatment, indicating that loss of
Cav1 enhanced MAPK and AP-1 transcription factor acti-
vation (Figure 5C). Finally, shCav1 cells stimulated by997
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Figure 4 Cav1 overexpression decreases migration,
invasion, and expression of K8 and K18 in PAM212
cells. A: By using 10% serum as a chemoattractant,
transwell assays show that Cav1 overexpression
decreases the ability of PAM212 to migrate and invade
(n  3 per group). B: Western blot analysis shows that
Cav1 overexpression decreases the expression of both
K8 and K18. Results are reported as means  SEM.
*P < 0.05, **P < 0.01 by the unpaired t-test.
Trimmer et aleither serum or EGF showed an increase in the expression of
K18, an AP-1eresponsive gene,32,38e41 and its binding
partner, K8. This phenotype was reversed by Cav1 over-
expression (Figure 4B). These ﬁndings were consistent with
our in vivo results (Figure 3B) and with previous studies that
have shown that K8 and K18 expression positively corre-
lated with invasive potential in several cell types,42e45
including PAM212,33 and in mouse and human skin
tumors.29,33 In addition, RT-qPCR analysis of AP-1 target
genes in Cav1 knockdown cells revealed increased expres-
sion of genes associated with tumor growth and invasion
(Figure 5D).
Collectively, these data indicated that the MAPK
pathway was hyperactivated in Cav1 knockdown cells in
response to two different growth stimuli, which, in turn,
increased AP-1 activation and increased transcription of
AP-1 target genes.998Dual Inhibition of Erk1/2 and JNK Decreases
Expression of K18 and Eliminated the Invasive
Advantage Conferred by Cav1 Knockdown in PAM212
Cells
To assess the functional signiﬁcance of MAPK activation in
shCav1 PAM212 cells, we treated cells with inhibitors for
both the Erk1/2 and JNK pathways. JNK is another activator
of AP-1 signaling through its ability to phosphorylate c-Jun.
U0126 is an MAPK inhibitor, a molecule that activates
Erk1/2, and SP600125 is a JNK inhibitor. We conﬁrmed
that 40 mmol/L of each inhibitor was sufﬁcient to decrease
its respective signaling pathways (Figure 6A). In addition,
we veriﬁed that inhibiting these pathways decreased the
expression of K18. Maximum inhibition of K18 expression
occurred when both pathways were inhibited, indicating
both pathways were contributing to the expression of thisFigure 5 Cav1 knockdown increases MAPK
pathway activation in response to serum or stimu-
lation with EGF. A: Western blot analysis of shCtl
and shCav1 PAM212 cells grown in complete media
with serum (left panel) or serum starved for 18
hours and treated with 50 ng/mL EGF (right panel).
Cav1 knockdown cells treated with EGF show an
increase in EGFR activation. When grown in either
complete or EGF-supplemented media, Cav1
knockdown cells show an increase in activated
Erk1/2. B: Cav1 knockdown increases the ability of
PAM212 to migrate and invade through transwell
chambers when EGF is used as the chemoattractant
in serum-free conditions (n 3 per group). Results
are reported as means  SEM. *P < 0.05, ***P <
0.001 by the unpaired t-test. C: Examination of
signaling molecules downstream of MAPK activa-
tion reveals that shCav1 cells grown in serum or EGF
show an increase in total c-Fos protein and acti-
vated c-Jun, an indication that these cells have
increased activity of the AP-1 transcription factor.
In addition, Cav1 knockdown increases expression
of K18, an AP-1eresponsive gene, and its binding
partner, K8. D: RT-qPCR analysis shows increased
expression of AP-1 target genes in Cav1 knockdown
PAM212 cells (n Z 3 per group). Results are re-
ported as means  SEM. *P < 0.05 by Dunnet’s
multiple comparisons test.
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Figure 6 Dual inhibition of Erk1/2 and JNK signaling decreases
expression of K18 and abolishes the invasive difference conferred by Cav1
knockdown in PAM212. A: Western blot analysis of PAM212 cells treated
with 40 mmol/L of U0126, an MAPK inhibitor, or SP600125, a JNK
inhibitor, either singly or in combination. Dual inhibition results in the
greatest decrease in K18. B: A Matrigel invasion assay shows that inhi-
bition of either Erk1/2 or JNK decreases the overall invasive ability of
both shCtl and shCav1 PAM212 cells, but does not eliminate the differ-
ence between the two groups. When both inhibitors are used in combi-
nation, the signiﬁcant difference in invasive ability conferred by Cav1
knockdown is abolished (n Z 3 per group). Results are reported as
means  SEM. **P < 0.01, ***P < 0.001 by the unpaired t-test. DMSO,
dimethyl sulfoxide.
Cav1 Modulates cSCC Growth and Invasionprotein. Finally, an invasion assay performed with these
inhibitors showed that both Erk1/2 and JNK inhibition
dramatically decreased the invasive ability of both shCtl and
shCav1 PAM212 cells; however, dual inhibition was
necessary to abolish the signiﬁcant increase in invasion
observed in shCav1 cells (Figure 6B). These results indi-
cated that the invasive advantage conferred by Cav1
knockdown was mediated through two different MAPK
pathways: Erk1/2 and JNK. In addition, K18 could be
a downstream mediator of the invasive phenotype, because
this was one protein that was affected by inhibition of these
two pathways.The American Journal of Pathology - ajp.amjpathol.orgCav1 Expression Is Decreased in the Human cSCC Cell
Line, SCC13, and Cav1 Overexpression Decreases
in Vitro Proliferation, Migration, and Invasion
To assess whether our results in PAM212 translated to human
cells, we used the human cSCC cell line, SCC13. We ﬁrst
compared Cav1 expression in these cells with that of the
human immortalized (ie, non-transformed) keratinocyte cell
line, HaCaT (Figure 7A). SCC13 carcinoma cells showed
a dramatic decrease in Cav1 and Cav2 expression compared
with noncancerous cells. Next, we successfully expressed
either pBabe empty vector or Cav1 overexpression vector in
these cells without altering Cav2 expression (Figure 7B).
Cav1 overexpression resulted in a signiﬁcant decrease in cell
growth, as evidenced by a growth curve (Figure 7C), and in
cell migration and invasion (Figure 7D), as evidenced by
transwell chamber assays. Surprisingly, despite the similar
phenotype conferred byCav1 overexpression in PAM212 and
SCC13, Erk activation and K18 expression levels were
largely unchanged by Cav1 overexpression in SCC13 cells
(Figure 7E). These results indicated that the inhibitory role of
Cav1 in growth and invasion acted through a different
mechanism than that observed in PAM212. However, these
data indicated that the phenotype conferred byCav1 inmurine
PAM212 cells could be recapitulated in the human cell line,
SCC13.Discussion
In the present study, we have examined the function of Cav1
in the development and progression of skin cancer. By using
a murine model of cutaneous squamous cell carcinoma, the
PAM212 cell line, we provide evidence that loss of Cav1
functions in primary tumor growth and also in the
progression of primary tumors into less-differentiated and
metastatic lesions. PAM212 cells are spontaneously trans-
formed BALB/c keratinocytes.18 They are commonly used
in skin research to study in vivo tumor growth,18 gene and
protein expression changes during tumor progression,46e51
and response to cytokines and chemicals.50e53 PAM212
cells form tumors with 100% incidence but display a lower
incidence of metastatic dissemination,48,54 making them an
ideal model to study changes in both tumor growth and
progression. By altering Cav1 expression in these cells, we
assessed the effect of this protein on both primary and
secondary tumor formation.
We ﬁrst show that Cav1 overexpression decreases cell
and tumor growth, whereas Cav1 knockdown increases
these attributes in PAM212 cells. Interestingly, knockdown
of Cav1 also affects the invasive characteristics of these
cells, as evidenced by an increase in the following: i)
in vitro migratory and invasive ability, ii) vessel density and
expression of K18 in primary tumors, and iii) incidence of
spontaneous lymph node metastasis. Finally, we show that,
in PAM212 cells stimulated with either serum or EGF, Cav1999
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Figure 7 Cav1 expression is decreased in the
human cSCC cell line, SCC13, and Cav1 over-
expression decreases in vitro proliferation, migra-
tion, and invasion. A: Western blot analysis shows
that Cav1 expression is decreased in SCC13
compared with the immortalized human keratino-
cyte cell line, HaCaT. Cav2 expression is also
decreased, whereas K14 expression is unaffected.
B: Western blot analysis shows successful over-
expression of Cav1 in SCC13, whereas Cav2 and
K14 expression levels are unaffected. C: Cav1
overexpression decreases cell growth in SCC13, as
indicated by a growth curve (nZ 3 per group). D:
Transwell assays show that overexpression of Cav1
decreases both the migratory and invasive ability
of these cells (n Z 4 per group). E: Western blot
analysis shows that Cav1 overexpression does not
affect Erk activation or the expression of K18.
Results are reported as means  SEM. *P < 0.05,
**P < 0.01 by the unpaired t-test. GAPDH, glyc-
eraldehyde-3-phosphate dehydrogenase.
Trimmer et alknockdown increases Erk1/2 MAPK pathway and AP-1
transcription factor activation. We attribute the increase in
invasive ability observed in Cav1 knockdown cells to
downstream mediators of the MAPK and JNK pathways,
because dual inhibition of these pathways abolishes the
increase in invasion conferred by Cav1 knockdown. We
suggest K18 as one of these mediators. To our knowledge,
we provide the ﬁrst evidence that Cav1 functions in the
development and progression of cutaneous squamous cell
carcinoma.
Signiﬁcantly, we corroborated some of our results in
a human cSCC cell line, SCC13. SCC13 has substantially
lowered levels of both Cav1 and Cav2 compared with a non-
transformed human keratinocyte cell line. Overexpression of
Cav1 decreased in vitro proliferation, migration, and inva-
sion, but it did not affect Erk1/2 activation or K18 expression,
as observed in PAM212 cells. One possible explanation is that
the level of Cav1 overexpression in SCC13 is lower than that
observed in PAM212 cells, potentially making the phenotype
less striking. These results indicate that Cav1 functions in the
modulation of themalignant phenotype through a different, as
yet undetermined, mechanism that is independent of MAPK
signaling in these cells.
Our work demonstrates that altered Cav1 expression
affects the growth of primary PAM212 tumors and also their
level of differentiation and their ability to invade surrounding
tissues and metastasize. Given this, we sought to determine
a mechanism for the effect of Cav1 on these aspects of tumor
biological characteristics. The MAPK pathways are key
regulators of cellular proliferation55,56 and are frequently
hyperactivated in cancer.57e59 One of the downstream
mediators of both the Ras-Erk1/2 and the JNK MAPK
cascades is the AP-1 transcription factor, composed of both1000c-Fos and c-Jun proteins.60e62 Previous work has implicated
Cav1 in the negative regulation of the Ras-Erk1/2 MAPK
cascade63,64 andAP-1 transcription factor activation.65,66 Our
current work establishes Cav1 as a key regulator of Erk1/2
MAPK pathway activation in PAM212. By using two
different stimuli, we showed increased Erk1/2 activation in
Cav1 knockdownPAM212 cells. In turn, this corresponded to
an increase in the expression and activation ofAP-1members,
speciﬁcally c-Fos and c-Jun. Interestingly, MAPK and AP-1
activation affects the expression of proteins that promote
both proliferation and invasion.
The Ras-Erk1/2 MAPK cascade is a critical controller of
cell cycle progression in many cell types. Activated Erk1/2
positively regulates cell cycle progression in several ways
by contributing to ribosomal RNA and protein synthesis in
preparation for translation and inducing positive regulators
of cell cycle progression.56,59 In addition, Erk1/2 activation
is essential to G1-to-S phase progression in many cell types.
This is accomplished through increasing the expression and
stabilization of AP-1 transcription factor members, which,
in turn, promote expression of cyclin D1.55 Interestingly, we
show that overexpression of Cav1 decreases cyclin D1
expression, whereas knockdown increases expression in
PAM212. Our results indicate that Cav1 knockdown results
in hyperactivation of the MAPK pathway, which, in turn,
drives proliferation in these cells.
Erk1/2 and AP-1 activation have also been implicated as
positive regulators of migration, invasion, and metastasis.
Speciﬁcally, activated Erk1/2 phosphorylates members of
focal adhesions promoting motility and, via AP-1, it can
induce expression of matrix metalloproteinases that promote
extracellular matrix breakdown and invasion.58,59 In addi-
tion, previous work has shown that the K18 gene has anajp.amjpathol.org - The American Journal of Pathology
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Cav1 Modulates cSCC Growth and InvasionAP-1eresponsive element.32,38e41 K18 and its binding
partner, K8, are intermediate ﬁlament molecules normally
expressed in non-stratiﬁed epithelia.32 Interestingly, Cav1
knockdown cells show an increase in both K8 and K18,
whereas cells in which Cav1 is overexpressed show
a decrease in these keratins. K8 and K18 have been asso-
ciated with increased invasion in a variety of cell types.42e45
Recently, Yamashiro et al33 have shown that lymph node
metastatic derivatives of PAM212 (LY-1 and 2) overexpress
both K8 and K18 compared with parental PAM212 cells.
Furthermore, the overexpression of K8 and K18 in parental
PAM212 confers a more invasive phenotype. Previous work
has also shown that both keratins are aberrantly expressed in
skin tumors, particularly in less-differentiated areas, and are
associated with invasion in human cSCC.29,33 Given this
work, we hypothesized that K8 and K18 are mediators of
the phenotype observed in Cav1 knockdown PAM212 cells.
Although previous work has shown that the K8 promoter
contains binding sites for the Ras/Erk1/2-responsive Ets
transcription factors, relatively little is known about K8
gene regulation32,67; therefore, we sought to inhibit K18
expression by exploiting its known regulation by AP-1. We
show that Erk1/2 inhibition modestly decreases K18
expression; to achieve maximum inhibition of K18, it is
necessary to dually inhibit both Erk1/2 and JNK, another
activator of AP-1 activity. Dual inhibition rescues the
increase observed in invasive ability when Cav1 is knocked
down in these cells. This dual contribution of the Erk1/2 and
JNK MAPK pathways to cancer development has also been
reported in melanoma, in which the two pathways can
operate in a feed-forward mechanism, contributing to tran-
scription of downstream target genes, such as cyclin D1.68
These results indicate that Cav1 knockdown increases
activation of Erk1/2 and AP-1, which, in turn, increase
invasive ability; in addition, one of the potential down-
stream mediators of this phenotype is K18. Our results are
interesting given previous studies showing a potential role
for Cav1 in both normal skin homeostasis and skin tumor
biological characteristics.
Previous work has shown that Cav1 is strongly expressed
in the basal layer of both murine and human skin,14,69 and
that expression of Cav1 is lost in a portion of human cSCC
tumors.17 Mechanistically, loss of Cav1 in a subpopulation
of human tumors could be an independent event in tumor
development or could occur secondarily to other signaling
events. As an autonomous event, Cav1 expression or
function is lost in various cancers because of the following:
i) loss of the chromosomal fragile site where the human
CAV1 gene is located,70e72 ii) aberrant promoter methyl-
ation,73e76 or iii) protein mislocalization due to muta-
tion.73,77 Alternatively, loss of Cav1 in skin tumors could
be a consequence of other molecular events. For example,
previous work has shown that cellular transformation
with the H-RasG12V oncogene decreases Cav1 promoter
activity78 and results in down-regulation of both caveolin-1
mRNA and protein.79 Moreover, p53 is a positive regulatorThe American Journal of Pathology - ajp.amjpathol.orgof Cav1 gene transcription.80 Therefore, p53 loss or Ras
activation, two alterations commonly observed in skin
cancer,81e84 could both negatively affect Cav1 expression,
providing a potential mechanism by which a decrease in
Cav1 protein levels is observed in a subpopulation of
cutaneous squamous cell carcinomas. However, the amount
of Cav1 expressed in skin tumors with these other molecular
alterations could subsequently affect cellular signaling,
altering the course of tumor development and progression in
this type of cancer. In relation to our current ﬁndings, loss of
Cav1 after Ras activation could result in a positive feedback
loop with even greater Erk1/2 MAPK activation and
increased expression of downstream molecules, such as
cyclin D1 and K18. Interestingly, we ﬁnd that our PAM212
cells express constitutively active Ras (RasG12V) and that
the expression of this protein is increased by Cav1 knock-
down and decreased by Cav1 overexpression (Supplemental
Figure S3). These results show that, in the context of
oncogenic Ras signaling, loss of Cav1, in this case through
genetic manipulation, is able to function in a positive
feedback loop by augmenting expression of the oncogene.1001
Trimmer et alPresumably, this augmentation could exacerbate the
malignant phenotype, as demonstrated herein by our work
in PAM212. The expression level of Cav1, therefore, could
be an important modiﬁer of the skin tumor phenotype.
Our results show that Cav1 affects two major aspects of
skin tumor biological characteristics: proliferation and growth
of primary tumors and invasion and metastasis to secondary
sites. We implicate Cav1 as a modulator of the Ras-Erk1/2
MAPK cascade and AP-1 transcription factor activity. These
proteins affect both proliferation and invasion (Figure 8). Our
data show that Cav1 knockdown increases the ability of
PAM212 cells to colonize a secondary site. As in many
cancers, patientmortalitywith cSCC is signiﬁcantly increased
in metastatic disease.5,85 In human tumors, characteristics
such as tumor size, degree of differentiation, and involvement
of vasculature are used to assess risk ofmetastasis.6,7 By using
a murine model of cSCC, we show that Cav1 knockdown
increases tumor size, vessel density, and invasiveness. To our
knowledge, this is theﬁrst study to indicate that Cav1 could be
a modulator of invasive and metastatic potential in cutaneous
squamous cell carcinoma. In conclusion, we show that Cav1
negatively regulates both the proliferative and invasive
capacity of murine cSCC cells and that this is mechanistically
associated with inhibition of MAPK and AP-1 activation.Supplemental Data
Supplemental material for this article can be found at
http://dx.doi.org/10.1016/j.ajpath.2012.11.008.References
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